2901 Hubbard Road, Suite 2723
Ann Arbor, MI 48109
Available to mentor
Navid Seraji-Bozorgzad, MD, is an associate professor of neurology in the University of Michigan Medical School.
Dr. Seraji-Bozorgzad began work in the area of medical imaging in 1990 as a research assistant during his undergraduate studies at the University of Michigan. He became familiar and developed a fundamental understanding of image acquisition and processing from his work on solid-state imaging arrays. After undergraduate work, he worked in the private sector as a software engineer, designing databases for various companies, including Ford Motor Company, and Liberty Mutual Insurance. The work provided him with experience in data-mining and manipulation of large datasets.
His passion for medicine eventually led him to medical school. During the application process he worked in the Department of Psychiatry and Behavioral Neurosciences, and eventually enrolled in graduate school in neuroscience. While in the Department of Psychiatry, he participated in the use of various MR imaging techniques, including magnetic resonance spectroscopy and functional MRI for diagnosis and disease progression in mood disorders, including bipolar disorder. It was during his graduate studies that he developed an interest in the field of neurodegeneration, regeneration and neuroprotection.
Dr. Seraji-Bozorgzad's research interest is primarily with non-invasive methods of monitoring disease progression in neurodegenerative disorders, with the ultimate goal of developing a tool set to monitor the efficacy of therapies early on in neurodegenerative disorders.
His bibliography includes numerous peer-reviewed jornals and publications, abstracts and other media.
Non-invasive methods of monitoring disease progression in neurodegenerative disorders.
-
Deelchand DK, Berrington A, Noeske R, Joers JM, Arani A, Gillen J, Schär M, Nielsen J-F, Peltier S, Seraji-Bozorgzad N, Landheer K, Juchem C, Soher BJ, Noll DC, Kantarci K, Ratai EM, Mareci TH, Barker PB, Öz G. NMR Biomed, 2021 May; 34 (5): e4218Journal ArticleAcross-vendor standardization of semi-LASER for single-voxel MRS at 3T.
DOI:10.1002/nbm.4218 PMID: 31854045 -
Zutshi D, Yarraguntla K, Mahulikar A, Seraji-Bozorgzad N, Shah AK, Basha MM. J Neurol Sci, 2020 May 15; 412: 116742Journal ArticleRacial variations in lacosamide serum concentrations in adult patients with epilepsy.
DOI:10.1016/j.jns.2020.116742 PMID: 32126366 -
Sweidan W, Bao F, Bozorgzad N-S, George E. J Neuroimaging, 2020 May; 30 (3): 351 - 358.Journal ArticleWhite and Gray Matter Abnormalities in Manifest Huntington's Disease: Cross-Sectional and Longitudinal Analysis.
DOI:10.1111/jon.12699 PMID: 32128927 -
Rao S, Stino A, Seraji-Bozorgzad N, Shah AK, Basha MM. Epilepsy Res, 2020 Feb; 160: 106281Journal ArticleSeizure-related injury and postictal aggression in refractory epilepsy patients.
DOI:10.1016/j.eplepsyres.2020.106281 PMID: 31981794 -
Sweidan W, Seraji-Bozorgzad N, Stanley J, George E. MOVEMENT DISORDERS, 2020 35: S285 - S286.Proceeding / Abstract / PosterDiffusion Magnetic Resonance Imaging with Neurite Orientation and Dispersion Imaging (NODDI) Detects Early Localized Cortex Disruption in Parkinson's Disease
-
Yarraguntla K, Bao F, Lichtman-Mikol S, Razmjou S, Santiago-Martinez C, Seraji-Bozorgzad N, Sriwastava S, Bernitsas E. Brain Sci, 2019 May 27; 9 (5):Journal ArticleCharacterizing Fatigue-Related White Matter Changes in MS: A Proton Magnetic Resonance Spectroscopy Study.
DOI:10.3390/brainsci9050122 PMID: 31137831 -
Malik S, Sriwastava S, Srinivas M, Seraji-Bozorgzad N, George E. Neurology, 2019 Apr 9; 92 (15_supplement):Journal ArticleA Previously Undescribed Case of an Autoimmune Cerebellar Ataxia (ACA) Associated with a Novel Antibody Against Mouse Cerebellum. (P2.2-041)
DOI:10.1212/wnl.92.15_supplement.p2.2-041 -
Ebrahim A, Alalawi Z, Yarraguntla K, Bao F, Alhaidar M, Lichtman-Mikol S, Razmjou S, Seraji-Bozorgzad N, Bernitsas E. Neurology, 2019 Apr 9; 92 (15_supplement):Journal ArticleCorrelation between Magnetization Transfer Ratio and Functional Status in Multiple Sclerosis patients (P5.2-046)
DOI:10.1212/wnl.92.15_supplement.p5.2-046